

FORM PTO-1595 (Modified)
(Rev. 03-01)
OMB No. 0551-0027 (exp. 5/31/2002)
P03/REV04

RECORDATION FORM COVER SHEET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

PATENTS ONLY

Tab settings → → → ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Jones Pharma Incorporated

Additional names(s) of conveying party(ies) ☐ Yes ☒ No

3. Nature of conveyance:

- ☐ Assignment ☒ Merger
☐ Security Agreement ☒ Change of Name
☐ Other _____

Execution Date: **December 1, 2004**

2. Name and address of receiving party(ies):

Name: **King Pharmaceuticals Research and Development, Inc.**

Internal Address: _____

Street Address: **501 Fifth Street**City: **Bristol** State: **TN** ZIP: **37620**Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s) Filing Date

B. Patent No.(s)

5,714,607	6,407,128
5,994,338	6,555,581
6,187,746	6,683,102
	7,005,416

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: **Christopher A. Klein**

Internal Address: _____

Street Address: **400 Crossing Blvd.**City: **Bridgewater** State: **NJ** ZIP: **08807**6. Total number of applications and patents involved: **7**7. Total fee (37 CFR 3.41):.....\$ **280.00**☐ Enclosed - Any excess or insufficiency should be credited or debited to deposit account☒ Authorized to be charged to deposit account

8. Deposit account number:

50-3706

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Christine L. O'Rourke

Name of Person Signing

Christine L. O'Rourke

Signature

March 6, 2007

Date

Total number of pages including cover sheet, attachments, and document: **9**Mail documents to be recorded with required cover sheet information to:
Patent and Trademark Office, P.O. Box 1400, Alexandria, VA 22304-1400

PATENT

Delaware


PAGE 1

The First State

I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"JONES PHARMA INCORPORATED", A DELAWARE CORPORATION,
WITH AND INTO "KING PHARMACEUTICALS RESEARCH AND
DEVELOPMENT, INC." UNDER THE NAME OF "KING PHARMACEUTICALS
RESEARCH AND DEVELOPMENT, INC.", A CORPORATION ORGANIZED AND
EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED
AND FILED IN THIS OFFICE THE FIRST DAY OF DECEMBER, A.D. 2004,
AT 7:06 O'CLOCK P.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE
NEW CASTLE COUNTY RECORDER OF DEEDS.



2417050 8100M

040864989

*Harriet Smith Windsor*Harriet Smith Windsor, Secretary of State
AUTHENTICATION: 3512433

DATE: 12-01-04

PATENT

**STATE OF DELAWARE
DELAWARE INTO DELAWARE
AGREEMENT OF MERGER**

Now on this 1st day of December, 2004, King Pharmaceuticals Research and Development, Inc. and Jones Pharma Incorporated, both Delaware Corporations, pursuant to Section 251 of the General Corporation Law of the State of Delaware, have entered into the following Agreement of Merger:

WITNESSETH that:

WHEREAS, the respective Boards of Directors of the foregoing named corporations deem it advisable that the corporations merge into a single corporation as hereinafter specified; and

WHEREAS, said King Pharmaceuticals Research and Development, Inc. filed its Certificate of Incorporation in the office of the Secretary of State of the State of Delaware on July 7, 1994; and

WHEREAS, said Jones Pharma Incorporated filed its Certificate of Incorporation in the office of the Secretary of State of the State of Delaware on March 24, 1981;

NOW, THEREFORE, the corporations, parties to this Agreement, by and between their respective Boards of Directors, in consideration of the mutual covenants, agreements and provisions hereinafter contained, do hereby prescribe the terms and conditions of said merger and of carrying the same into effect as follows:

FIRST: King Pharmaceuticals Research and Development, Inc. hereby merges into itself Jones Pharma Incorporated and said Jones Pharma Incorporated shall be and hereby is merged into King Pharmaceuticals Research and Development, Inc., which shall be the surviving corporation.

SECOND: The Certificate of Incorporation and bylaws of King Pharmaceuticals Research and Development, Inc., as in effect on the date of the merger

PATENT


provided for in this Agreement, shall continue in full force and effect as the Certificate of Incorporation and bylaws of the corporation surviving this merger. The directors and officers of King Pharmaceuticals Research and Development, Inc. shall continue as the directors and officers of the corporation surviving this merger.

THIRD: The manner of converting the outstanding shares of each of the constituent corporations shall be as follows: Each two shares of the common stock of Jones Pharma Incorporated, \$0.01 par value per share, shall be converted into one share of common stock of King Pharmaceuticals Research and Development, Inc., \$0.01 par value per share.


FOURTH: This merger shall become effective upon filing with the Secretary of State of Delaware.

IN WITNESS WHEREOF, the parties to this Agreement, pursuant to authority duly given by their respective Boards of Directors, have caused these presents to be executed by an authorized officer of each party hereto.

**King Pharmaceuticals Research and
Development, Inc.**

By: 
Name: John A. A. Bellamy
Title: Executive Vice-President, General
Counsel and Secretary


Jones Pharma Incorporated

By: 
Name: John A. A. Bellamy
Title: Executive Vice-President, General
Counsel and Secretary

PATENT

I, John A. A. Bellamy, Secretary of Jones Pharma Incorporated, a corporation organized and existing under the laws of the State of Delaware, hereby certify, as such Secretary of the said corporation, that the Agreement of Merger to which this certificate is attached, after having been first duly signed on behalf of said corporation by an authorized officer of Jones Pharma Incorporated, a corporation of the State of Delaware, was duly submitted to the stockholders of said Jones Pharma Incorporated, at a special meeting of said stockholders (or written consent in lieu thereof) called and held separately from the meeting of stockholders of any other corporation, upon waiver of notice, signed by all the stockholders, for the purpose of considering and taking action upon said Agreement of Merger, that 1,000 shares of stock of said corporation were on said date issued and outstanding and that the holders of 1,000 shares voted by ballot in favor of said Agreement of Merger and the holders of 0 shares voted by ballot against same, the said affirmative vote representing at least a majority of the total number of shares of the outstanding capital stock of said corporation, and that thereby the Agreement of Merger was at said meeting duly adopted as the act of the stockholders of said Jones Pharma Incorporated, and the duly adopted agreement of said corporation.

WITNESS my hand on behalf of said Jones Pharma Incorporated on this 1st day of December, 2004.


By:  Secretary

Name: John A. A. Bellamy

PATENT

I, John A. A. Bellamy, Secretary of King Pharmaceuticals Research and Development, Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certify, as such Secretary of the said corporation, that the Agreement of Merger to which this certificate is attached, after having been first duly signed on behalf of said corporation by an authorized officer of King Pharmaceuticals Research and Development, Inc., a corporation of the State of Delaware, was duly submitted to the stockholders of said King Pharmaceuticals Research and Development, Inc., at a special meeting of said stockholders (or written consent in lieu thereof) called and held separately from the meeting of stockholders of any other corporation, upon waiver of notice, signed by all the stockholders, for the purpose of considering and taking action upon said Agreement of Merger, that 1,000 shares of stock of said corporation were on said date issued and outstanding and that the holders of 1,000 shares voted by ballot in favor of said Agreement of Merger and the holders of 0 shares voted by ballot against same, the said affirmative vote representing at least a majority of the total number of shares of the outstanding capital stock of said corporation, and that thereby the Agreement of Merger was at said meeting duly adopted as the act of the stockholders of said King Pharmaceuticals Research and Development, Inc., and the duly adopted agreement of said corporation.

WITNESS my hand on behalf of said King Pharmaceuticals Research and Development, Inc. on this 1st day of December, 2004.

By:  _____
Secretary

Name: John A. A. Bellamy

PATENT

**STATE OF DELAWARE
CERTIFICATE OF MERGER OF
DOMESTIC CORPORATIONS**

Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law, the undersigned corporation executed the following Certificate of Merger:

FIRST: The name of the surviving corporation is **King Pharmaceuticals Research and Development, Inc.**, and the name of the corporation being merged into this surviving corporation is **Jones Pharma Incorporated**.

SECOND: The Agreement of Merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations.

THIRD: The name of surviving corporation is **King Pharmaceuticals Research and Development, Inc.**, a Delaware corporation.

FOURTH: The Certificate of Incorporation of the surviving corporation shall be its Certificate of Incorporation.

FIFTH: The merger is to become effective on December 1, 2004.

SIXTH: The Agreement of Merger is on file at 501 Fifth Street, Bristol, Tennessee 37620.

SEVENTH: A copy of the Agreement of Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the constituent corporations.

IN WITNESS WHEREOF, said surviving corporation has caused this certificate to be signed by an authorized officer, the 1st day of December, A.D., 2004.

By: 

Name: **John A. A. Bellamy**
Title: **Executive Vice President,
General Counsel and Secretary**

PATENT

State of Delaware
Secretary of State
Division of Corporations
Delivered 07:06 PM 12/01/2004
FILED 07:06 PM 12/01/2004
SRV 040864989 - 2417050 FILE

**STATE OF DELAWARE
CERTIFICATE OF MERGER OF
DOMESTIC CORPORATIONS**

Pursuant to Title 8, Section 251(c) of the Delaware General Corporation Law, the undersigned corporation executed the following Certificate of Merger:

FIRST: The name of the surviving corporation is King Pharmaceuticals Research and Development, Inc., and the name of the corporation being merged into this surviving corporation is Jones Pharma Incorporated.

SECOND: The Agreement of Merger has been approved, adopted, certified, executed and acknowledged by each of the constituent corporations.

THIRD: The name of surviving corporation is King Pharmaceuticals Research and Development, Inc., a Delaware corporation.

FOURTH: The Certificate of Incorporation of the surviving corporation shall be its Certificate of Incorporation.

FIFTH: The merger is to become effective on December 1, 2004.

SIXTH: The Agreement of Merger is on file at 501 Fifth Street, Bristol, Tennessee 37620.

SEVENTH: A copy of the Agreement of Merger will be furnished by the surviving corporation on request, without cost, to any stockholder of the constituent corporations.

IN WITNESS WHEREOF, said surviving corporation has caused this certificate to be signed by an authorized officer, the 1st day of December, A.D., 2004.

By: 

Name: John A. A. Bellamy
Title: Executive Vice President,
General Counsel and Secretary

PATENT